REG - IP Group PLC - Istesso update on P2b study of leramistat in RA

IPAnnouncement

17/02/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250217:nRSQ3274Xa&default-theme=true

RNS Number : 3274X  IP Group PLC  17 February 2025

 

 FOR RELEASE ON  17 February 2025

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF THE UK
VERSION OF THE MARKET ABUSE REGULATION (EU NO. 596/2014) WHICH FORMS PART OF
ENGLISH LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018.

 

IP Group plc - Portfolio company Istesso provides update on Phase 2b study of
leramistat in rheumatoid arthritis

 

·      Results reinforce leramistat's novel mechanism of action (MOA)
and effectiveness in bone protection in people living with rheumatoid
arthritis (RA).

·      Significant improvements were seen in the key secondary endpoint
of bone erosions as well as improvements in disability and fatigue in patients
treated with leramistat, despite the study not meeting the primary endpoint of
improvement in ACR20 versus placebo.

·      Results support further evaluation of leramistat's potential to
promote tissue repair in RA, as well as other chronic conditions. Istesso is
sufficiently funded to conduct additional studies.

 

IP Group plc (LSE: IPO), which invests in breakthrough science and innovation
companies with the potential to create a better future for all, is pleased to
provide the following update now that Istesso Limited has provided its
shareholders with the outcome of its Phase 2b study of leramistat in
rheumatoid arthritis (RA).

The leramistat phase 2b study was a 12-week randomised, double-blind,
placebo-controlled trial in adults with moderate-severe RA and an inadequate
response to treatment with methotrexate. Although the study did not meet the
primary endpoint of improvements in ACR20 versus placebo, leramistat did
demonstrate statistically significant reductions in the key secondary endpoint
of bone erosions, as well as improvements in disability and fatigue.(1)

Istesso highlighted that these findings demonstrate leramistat's unique
mechanism of action (MOA) and support further evaluation of its potential to
promote adaptive tissue repair in combination with existing disease-modifying
anti-rheumatic drugs (DMARDs) in RA, as well as in other chronic conditions.

Istesso also drew attention to the fact that treatment with leramistat
significantly reduced or stopped the progression of bone erosions.(1) Bone
erosions are a central feature of RA and appear early in the course of the
disease. Progression of bone erosions leads to bone damage and is a major
driver of disability and increased mortality in people living with
RA.(2,3,4,5)

Improvements in structural damage were accompanied by statistically
significant benefits seen in reduced disability and fatigue for patients
receiving leramistat versus placebo.(1) Fatigue in RA is widespread and its
impact debilitating, affecting quality of life and is often cited as the
primary cause of inability to work and job loss.(6) Current treatment options
are limited and there remains a huge unmet clinical need.(6)

No new safety concerns were identified in the study. The adverse event (AE)
rate was similar between groups receiving leramistat and placebo, and the
majority of AEs were mild in nature and resolved without treatment.(1) No
deaths were reported and no significant changes in clinical chemistry, bloods,
vital signs or cardiovascular health have been noted in leramistat trials to
date.(7)

Istesso will publish full study results in due course and plans further Phase
2 studies to evaluate leramistat's unique potential to promote adaptive tissue
repair in RA, as well as other chronic conditions. Istesso is sufficiently
funded to conduct these studies.

IP Group has an undiluted holding of 56.5% in Istesso and anticipates
providing a further update on Istesso, including its valuation, in its 2024
results that will be published next month.

Greg Smith, Chief Executive Officer of IP Group, said: "We are encouraged that
these results are consistent with leramistat's unique mechanism of action
which supports and augments tissue repair. In addition, the impact on
disability and fatigue, from which a large proportion of RA patients continue
to suffer despite the widespread availability of current medications, is also
highly promising. Istesso will carry out additional work to evaluate
leramistat's potential to address these unmet needs and to promote adaptive
tissue repair in RA and other chronic conditions, potentially in combination
with existing therapies. Based on these data, we continue to believe in the
market opportunity for leramistat to improve patients' health and deliver
significant value for shareholders."

For more information, please contact:

 

 IP Group plc                       www.ipgroupplc.com
 Liz Vaughan-Adams, Communications  +44 (0) 20 7444 0062/+44 (0) 7967 312125
 Portland
 Alex Donaldson                     +44 (0) 7516 729702

 

Notes for editors

 

About IP Group

 

IP Group accelerates the impact of science for a better future. As the most
active UK based, early stage science investor, we develop and support some of
the world's most exciting businesses in deeptech, life sciences and cleantech
(led by Kiko Ventures). Through Parkwalk, the UK's largest growth EIS fund
manager, we also back world-changing innovation emerging in leading
universities and research institutions. Our specialist investment team
combines sector expertise with an international approach. Together we have a
strong track record of success, having backed high-profile companies including
Oxford Nanopore Technologies plc, First Light Fusion, Hysata, and Oxa. IP
Group is listed on the Main Market of the London Stock Exchange under the code
IPO. For more information, please visit our website at www.ipgroupplc.com
(http://www.ipgroupplc.com/) .

 

About Istesso

Istesso is looking at chronic disease differently, focusing on repairing the
damage caused by debilitating chronic conditions rather than symptom control.
We stand apart, disrupting conventional thinking and seeking robust
science-led treatment solutions to enable patients to live free from chronic
disease. Scientists at heart, with almost 1000 years of drug discovery
expertise, we are the only company to understand and exploit the body's
natural biology of repair. Istesso is discovering and developing pioneering
transformative medicines that enhance the body's ability to repair, redefine
treatment expectations and make a lasting impact on patients' lives. To learn
more please visit us at: www.istesso.co.uk (http://www.istesso.co.uk)

 

About leramistat

Leramistat is an investigational first-in-class, once-daily pill currently in
phase 2 development. Its unique MOA augments the body's inherent repair
response to repair and restore damaged tissue and build resilience to further
damage without suppressing the immune system.(7) Leramistat has been shown to
reduce the progression of structural damage and improve bone dynamics,
disability and fatigue in people with RA.(7) With its good safety and
tolerability profile and a low likelihood of interactions with other
medicines, leramistat is ideally positioned as a potential combination therapy
in RA.(7)

( )

Leramistat offers the potential for disease resolution across a wide range of
therapeutic areas including chronic diseases of auto-inflammation,
autoimmunity, fibrosis or bone loss.(7) Leramistat has been granted both FDA
Fast Track and Orphan Drug Designation (ODD) to support its development and
expedite its review to fill an unmet medical need in idiopathic pulmonary
fibrosis (IPF).

 

About rheumatoid arthritis

RA is a destructive chronic and debilitating autoimmune disease causing severe
joint and tissue damage that can lead to disability and premature death
affecting approximately 17.6 million people globally.(9,10) This figure is
expected to double to ~31.7 million by 2050 and it is estimated that ~70% of
those affected will be female.(12) Bone erosions appear early in the course of
RA, often preceding diagnosis and up to 60% of patients have erosions within a
year leading to joint damage and causing impaired function and
disability.(2,4,5) Even with significant treatment advances, many patients
continue to show joint deterioration and disability, and rates of RA related
surgery remain relatively unchanged in many countries.(6,11)

 

The majority of people with RA also experience daily fatigue with significant
overwhelming exhaustion affecting up to 70% of patients, and almost three
quarters experiencing persistently high or worsening levels of fatigue.(6,12)
Fatigue is a key contributor to increased clinical care costs, primary care
consultations and employment loss, is poorly understood and managed and
current treatments have a minimal effect on fatigue.(7,12)

 

About the study

The leramistat phase 2b study was a 12-week randomised, double-blind,
placebo-controlled trial of men and women with moderate-severe RA and an
inadequate response to treatment with methotrexate (MTX). The primary endpoint
was efficacy of leramistat versus placebo as measured by ACR20. Secondary
endpoints included assessment of structural progression and subclinical
inflammation, clinical joint count composite assessments such as DAS28-CRP,
ACR20/50/70 over time, patient reported outcomes and change in hsCRP.(1) The
study is listed on ClinicalTrials.gov and can be accessed here:
https://clinicaltrials.gov/study/NCT05460832
(https://clinicaltrials.gov/study/NCT05460832) .

 

RA measures used in the study

ACR20(8) is a standardised RA clinical outcome measure developed by the
American College of Rheumatology to evaluate the efficacy of interventions in
RA clinical trials. ACR20 response is defined as at least 20% improvement from
baseline in the number of tender and swollen joints and in three of the
following five criteria: patient's assessment of pain by visual analogue scale
(VAS), patient's global assessment of disease activity, physician's global
assessment of disease activity, patient's assessment of physical function
measured by HAQ-DI and C-reactive protein (CRP).

 

1 Data on file - NCT05460832 (IST-06). Listed on NIH National Library of
Medicine Clinical Trials register. Available at:
https://clinicaltrials.gov/study/NCT05460832.

2 Panagopoulos PK et al. Bone erosions in rheumatoid arthritis: recent
developments in pathogenesis and therapeutic implications. J Musculoskelet
Neuronal Interact. 2018; 18(3):304-319.

3 Schett F et al. Bone erosion in rheumatoid arthritis: mechanisms, diagnosis
and treatment. Nat Rev Rheumatol. 2012; 8(11):6656-664.

4 Kleyer A et al. Bone loss before the clinical onset of rheumatoid arthritis
in subjects with anticitrullinated protein antibodies. Ann Rheum Dis. 2014;
73(5):854-60.

5 Pap T et al. Cartilage damage in osteoarthritis and rheumatoid
arthritis--two unequal siblings. Nat Rev Rheumatol. 2015; 11(10):606-15.

6 Dures E et al. 2023 EULAR recommendations for the management of fatigue in
people with inflammatory rheumatic and musculoskeletal diseases. Annals of the
Rheumatic Diseases. 2024; 83:1260-1267.

7 Data on file

8 MedwireNews. At a glance: common scores used in rheumatology. 2018.
Available at:
https://www.medwirenews.com/showcase/at-a-glance-common-scores-used-in-rheumatology/

9 Black RJ et al. Global regional, and national burden of rheumatoid
arthritis, 1990-2020, and projections to 2050: a systematic analysis of the
Global Burden of Disease Study 2021. The Lancet Rheumatology. 2023;
5(10):e594-e610.

10 World Health Organization. Factsheet: Rheumatoid arthritis; updated 28 June
2023. Available at:
https://www.who.int/news-room/fact-sheets/detail/rheumatoid-arthritis

11 Tominaga A et al. Surgical intervention for patients with rheumatoid
arthritis is declining except for foot and ankle surgery: A single-centre,
20-year observational cohort study. Modern Rheumatology. 2023; 33(3):509-516.

12 Druce KL et al. Predictors of fatigue in rheumatoid arthritis.
Rheumatology. 2019; 58(5):v29-v34.

 

ENDS

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCEAFAKFEPSEAA